¶ÈÀÓ¾Ò²ð

2003ǯ

¸¶ÃøÏÀʸ¡¿¾ÉÎãÊó¹ð

  1. Agartz I, Brag S, Franck J, Hammarberg A, Okugawa G, Svinhuvud K, Bergman H ; MR volumetry during acute alcohol withdrawal and abstinence: a descriptive study¡¥ Alcohol and Alcoholism 38:71-78
  2. Minami T, Nobuhara K, Okugawa G, Takase K, Yoshida T, Sawada S, Ha-Kawa S, Ikeda K, Kinoshita T ; Diffusion Tensor Magnetic Resonance Imaging of Disruption of Regional White Matter in Schizophrenia. Neuropsychobiology 47:141-145
  3. Okugawa G, Sedvall GC, Agartz I ; Smaller cerebellar vermis but not hemisphere volumes in chronic schizophrenia. The American Journal of Psychiatry 160:1614-1616
  4. Okugawa G, Takase K, Nobuhara K, Yoshida T, Minami T, Tamagaki C, Magnotta VA, Andreasen NC, Kinoshita T ; Inter- and Intraoperator reliability of brain tissue measures using magnetic resonance imaging. European Archives of Psychiatry and Clinical Neuroscience 253:301-306
  5. ±ä¸¶·òÆ󡤵ÈÅľ﹧¡¤²Ï ÁêµÈ¡¤µÈ¼¶©»Ë¡¤Æî Ãҵס¤ÀÄÌÚÎɽ㡤߷ÅÄ ÉÒ¡¤ÌÚ²¼Íøɧ ; ÈÕȯÀ­¥¢¥ë¥Ä¥Ï¥¤¥Þ¡¼É´µ¼Ô¤Ë¤ª¤±¤ëÌôʪ¼£ÎŸú²ÌȽÄê¤Ë´Ø¤¹¤ëSPECT¸¦µæ. Intervision 18:57
  6. µÈ¼¶©»Ë¡¤°ëë½ÓÌÀ¡¤ÌøÀ¸Î´»ë¡¤µÈÅľ﹧¡¤ÌÚ²¼Íøɧ ; ¡ÚÌôʪǾÇȳؤοÊÊâ¡Û¿·¤·¤¤Ç¾Çȶõ´Ö²òÀϼêË¡¤Î±þÍÑ ·Ú¾É¥¢¥ë¥Ä¥Ï¥¤¥Þ¡¼·¿ÃÔÊò¤ÎǾÅŰ̾칽¤¤È¤½¤Î±ö»À¥É¥Í¥Ú¥¸¥ë¤Ë¤è¤ëÊѲ½¡¥ Î×¾²¿À·ÐÀ¸Íý³Ø31:5-12
  7. ʬÌîÀµµ®¡¤ÌøÀ¸Î´»ë¡¤Æþß· Áë Ëü´î»Ò¡¤ÌÚ²¼Íøɧ ; Åŵ¤¤±¤¤¤ì¤óÎÅË¡¤¬ÁÕ¸ú¤·¤¿Pisa¾É¸õ·²¤òÄ褹¤ëʬÎö´¶¾ð¾ã³²¤Î°ìÎã¡¥ Àº¿À°å³Ø 11:1215-1218
  8. ʬÌîÀµµ®¡¤ÌøÀ¸Î´»ë¡¤Æþß· Áë Ëü´î»Ò¡¤ÌÚ²¼Íøɧ ; 謁£ÎŤÈmianserin¤¬ÁÕ¸ú¤·¤¿ðôÉô¥¸¥¹¥È¥Ë¥¢¤òÀ¸¤¸¤¿¤¦¤ÄɤΰìÎã¡¥ Àº¿À²Ê¼£ÎÅ³Ø 7:811-816
  9. Æî Ãҵס¤±ä¸¶·òÆ󡤱üÀî ³Ø¡¤µÈ¼¶©»Ë¡¤µÈÅľ﹧¡¤¹âÀ¥¾¡¶µ¡¤ÃÓÅĹ̻Ρ¤²Ï ÁêµÈ¡¤ß·ÅÄ ÉÒ¡¤ÌÚ²¼Íøɧ ; Åý¹ç¼ºÄ´¾É¤Ë¤ª¤±¤ëǾÇò¼Á¤Î³È»¶°ÛÊýÀ­. Ǿ¤ÈÀº¿À¤Î°å³Ø 14:261-268
  10. Æî Ãҵס¤±ä¸¶·òÆ󡤱üÀî ³Ø¡¤µÈÅľ﹧¡¤¹âÀ¥¾¡¶µ¡¤ÅĶᰡÍö¡¤ÌøÀ¸Î´»ë¡¤²Ï ÁêµÈ¡¤ß·ÅÄ ÉÒ¡¤ÌÚ²¼Íøɧ ; ¹âÎð¼Ô¤¦¤ÄÉ´µ¼Ô¤Ë¤ª¤±¤ëÅŵ¤¤±¤¤¤ì¤óÎÅË¡¤ÎÂçǾ¤Î¶É½êǾ·ìή¤ª¤è¤Ó³È»¶°ÛÊýÀ­¤ËµÚ¤Ü¤¹±Æ¶Á¤Ë¤Ä¤¤¤Æ.Âçºå¤Æ¤ó¤«¤ó¸¦µæ²ñ»¨»ï14:7-14
  11. °ëë½ÓÌÀ¡¤ºûÅĶ¯Ê¼¡¤Ê¬ÌîÀµµ®¡¤ÅĶᰡÍö¡¤µÈ¼¶©»Ë¡¤Æþß· Á¿ù»³Í´Éס¤ã·Æ£Ä¾Ì¦¡¤ÌøÀ¸Î´»ë¡¤ÌÚ²¼Íøɧ ; ¼ï¡¹¤ÎºÅ̲°Å¼¨¤¬¶õ´ÖŪǾÅŰ̳èÆ°¤ËµÚ¤Ü¤¹±Æ¶Á.
    ºÅ̲¤È²Ê³Ø 18:49-54
  12. µÈÅľ﹧¡¤²Ï ÁêµÈ¡¤µÈ¼¶©»Ë¡¤Æî Ãҵס¤ÀÄÌÚÎɽ㡤±ä¸¶·òÆó¡¤ÌÚ²¼Íøɧ¡¤ß·ÅÄ ÉÒ ; ¥¢¥ë¥Ä¥Ï¥¤¥Þ¡¼É 123I-IMP ARGË¡¤òÍѤ¤¤¿Ç¾·ìήSPECT¤È¼£ÎŸú²Ìͽ¬¤Î²ÄǽÀ­ Î×¾²Êü¼ÍÀþ48(2)305-310
  13. ¿¥ÅÄ͵¹Ô¡¤ÅĶᰡÍö¡¤²ÃÆ£Àµ¼ù¡¤°ëë½ÓÌÀ¡¤ÌÚ²¼Íøɧ ; ̵¾²Áí¹çɱ¡¿´ÎÅÆâ²Ê³°Íè¤Î·Ð¸³¤«¤é¡Ý¸Â¤é¤ì¤¿¼£ÎÅ´Ø·¸¤ÎÃæ¤ÇÌôʪÎÅË¡¤Î²Ì¤¿¤¹Ìò³ä¡Ý¡¥¶¯Ç÷À­¾ã³²¤Î¸¦µæ£´:39-44

¥Ú¡¼¥¸TOP¤ØÌá¤ë

Ãø½ñ

  1. ÌÚ²¼Íøɧ¡¤¿¥ÅÄ͵¹Ô ; Àº¿À°å³Ø¾É¸õ·²­¶¡½ÀÝ¿©¡¦¿ç̲¡¦À­¡¦¿Í³Ê¾ã³²¤Ê¤É¡½
    ­ºÀ­¾ã³² À­µ¡Ç½ÉÔÁ´ À­´ïÈ¿±þÉÔÁ´¡¥ÆüËÜÎ×à® ÎΰèÊ̾ɸõ·²¥·¥ê¡¼¥º39 pp261-264
  2. ÌÚ²¼Íøɧ¡¤¿¥ÅÄ͵¹Ô ; Àº¿À°å³Ø¾É¸õ·²­¶¡½ÀÝ¿©¡¦¿ç̲¡¦À­¡¦¿Í³Ê¾ã³²¤Ê¤É¡½
    ­ºÀ­¾ã³² À­µ¡Ç½ÉÔÁ´ ¥ª¥ë¥¬¥º¥à¾ã³².ÆüËÜÎ×à® ÎΰèÊ̾ɸõ·²¥·¥ê¡¼¥º39 pp265-267
  3. ÌÚ²¼Íøɧ¡¤¿¥ÅÄ͵¹Ô ; Àº¿À°å³Ø¾É¸õ·²­¶¡½ÀÝ¿©¡¦¿ç̲¡¦À­¡¦¿Í³Ê¾ã³²¤Ê¤É¡½
    ­ºÀ­¾ã³² À­µ¡Ç½ÉÔÁ´ Ááϳ¡¥ÆüËÜÎ×à® ÎΰèÊ̾ɸõ·²¥·¥ê¡¼¥º39 pp268¡Ý270
  4. ÌÚ²¼Íøɧ¡¤¿¥ÅÄ͵¹Ô ; Àº¿À°å³Ø¾É¸õ·²­¶¡½ÀÝ¿©¡¦¿ç̲¡¦À­¡¦¿Í³Ê¾ã³²¤Ê¤É¡½
    ­ºÀ­¾ã³² À­µ¡Ç½ÉÔÁ´ ʪ¼ÁͶȯÀ­À­µ¡Ç½ÉÔÁ´¡¥ÆüËÜÎ×à® ÎΰèÊ̾ɸõ·²¥·¥ê¡¼¥º39 pp280¡Ý282
  5. ±ä¸¶·òÆó ; Àº¿À¾ã³²¤ª¤è¤Ó¿´¿È¾É¤ÎÉÂÂ֤ȼ£ÎÅ. Åý¹ç¼ºÄ´¾É(³µÀâ)
    °ìḚ̀塦¸¦½¤°å¤Î¤¿¤á¤Î¥á¥ó¥¿¥ë¥±¥¢.¥É¥é¥Ã¥°¥¬¥¤¥É 2004-05 pp148-149, 2003¥á¥Ç¥£¥«¥ë¥É¥¥ Åìµþ
  6. ±ä¸¶·òÆó ; Àº¿À¾ã³²¤ª¤è¤Ó¿´¿È¾É¤ÎÉÂÂ֤ȼ£ÎÅ. Åý¹ç¼ºÄ´¾É(ËýÀ­´ü)
    °ìḚ̀塦¸¦½¤°å¤Î¤¿¤á¤Î¥á¥ó¥¿¥ë¥±¥¢.¥É¥é¥Ã¥°¥¬¥¤¥É 2004-05 pp152-153, 2003¥á¥Ç¥£¥«¥ë¥É¥¥ Åìµþ
  7. ±ä¸¶·òÆó ; Àº¿À¾ã³²¤ª¤è¤Ó¿´¿È¾É¤ÎÉÂÂ֤ȼ£ÎÅ. Åý¹ç¼ºÄ´¾É(¸¸³ÐÌÑÁÛ¾õÂÖ)
    °ìḚ̀塦¸¦½¤°å¤Î¤¿¤á¤Î¥á¥ó¥¿¥ë¥±¥¢.¥É¥é¥Ã¥°¥¬¥¤¥É 2004-05 pp154-155, 2003¥á¥Ç¥£¥«¥ë¥É¥¥ Åìµþ
  8. ¿¥ÅÄ͵¹Ô¡¤ÅĶᰡÍö¡¤²ÃÆ£Àµ¼ù¡¤°ëë½ÓÌÀ¡¤ÌÚ²¼Íøɧ ; ̵¾²Áí¹çɱ¡¿´ÎÅÆâ²Ê³°Íè¤Î·Ð¸³¤«¤é¡Ý¸Â¤é¤ì¤¿¼£ÎÅ´Ø·¸¤Î¤Ê¤«¤ÇÌôʪÎÅË¡¤Î²Ì¤¿¤¹Ìò³ä¡Ý. ¶¯Ç÷À­¾ã³²¤Î¸¦µæ4 pp39-44, 2003 À±Ï½ñŹ Åìµþ

¥Ú¡¼¥¸TOP¤ØÌá¤ë

2002ǯ

¸¶ÃøÏÀʸ¡¿¾ÉÎãÊó¹ð

  1. Isotani T, Kinoshita T, Lehmann D, Pascual- Marqui RD, Wackermann J ; Spatial configuration of brain electric activity during positive, neutral and negative emotions. Methods Find Exp Clin Pharmacol 24 (Suppl. D):109-110
  2. Okugawa G, Sedvall G, Nordstrom M, Andreasen NC, Pierson R, Magnotta V, Agartz I ; Selective reduction of the posterior superior vermis in men with chronic schizophrenia. Schizophrenia Research 55:61-67
  3. Okugawa G, Yagi A, Kusaka H, Kinoshita T ; Paroxetine for Treatment of Somatization Disorder. Journal of Neuropsychiatry and Clincal Neuroscience 14:464-46
  4. Okugawa G, Sedvall GC, Agartz I ; Reduced grey and white matter volumes in the temporal lobe of male patients with chronic schizophrenia. European Archives of Psychiatry and Clinical Neuroscience 252¡§120-123
  5. Irisawa S, Isotani T, Kinoshita T ; Spatial EEG Structure in Schizophrenia.
    Methods Find Exp Clin Pharmacol 24 (Suppl. D):111-112
  6. Park JR, Yagyu T, Saito N, Kinoshita T, Hirai T ; Dynamics of brain electric field during recall of salpuri dance performance. Perceptual and Motor skills95:955-962.
  7. Yoshimura M, Isotani T, Tamagaki C, Yoshida T, Sugiyama M, Sugimoto T, Yagyu T, Nagata M, KinoshitaT ; Global field power and low resolution electromagnetic tomography solutions in Alzheimer's disease. International Congress Series 1232¡§751-755
  8. µÈ¼¶©»Ë¡¤Ä¥ ³¤Î衤µÈÅľ﹧¡¤°ëë½ÓÌÀ¡¤±ä¸¶·òÆ󡤶̳ÀÀé½Õ¡¤Æþß· Á¿ùËÜãºÈ¡¤ÌøÀ¸Î´»ë¡¤ÌÚ²¼Íøɧ ; ·Ú¾É¥¢¥ë¥Ä¥Ï¥¤¥Þ¡¼É¤ÎǾÅž칽¤¤È¤½¤Î±ö»À¥É¥Í¥Ú¥¸¥ë¤Ë¤è¤ëÊѲ½¡¥ÆüËÜÌôʪǾÇȳزñ»¨»ï4¡§8¡¾11
  9. °ëë½ÓÌÀ¡¤µÈÅľ﹧¡¤µÈ¼¶©»Ë¡¤Æþß· Á¿ù»³Í´Éס¤Æî Ãҵס¤×¢ÅÄÂîÌ顤ã·Æ£Ä¾Ì¦¡¤±ä¸¶·òÆó¡¤ÌøÀ¸Î´»ë¡¤ÌÚ²¼Íøɧ ; AcetazolamideÀÅÌ®ÆâÅêÍ¿¤Ë¤è¤ëǾÇÈÊѲ½ ¡½Ç¾·ìήÁý²Ã¤È³Æ¼þÇÈ¿ôÂÓ°è¤Î¶õ´ÖŪǾÇȳèÆ°¤È¤Î´Ø·¸¡½(a pilot study)¡¥ÆüËÜÌôʪǾÇȳػ¨»ï4¡§84¡¾87
  10. µÈ¼¶©»Ë¡¤ÌøÀ¸Î´»ë¡¤±ä¸¶·òÆó¡¤Æþß· ÁµÈÅľ﹧¡¤Æî Ãҵס¤ÃæÊ¿¶Ç»Ò¡¤ÎëÌÚÈþº´¡¤°ëë½ÓÌÀ¡¤ÌÚ²¼Íøɧ ; ¥¢¥ë¥Ä¥Ï¥¤¥Þ¡¼É¤ÎǾÅžìÆ°ÂÖ²òÀϤˤè¤ë¸¡Æ¤.Î×¾²Ç¾ÇÈ44¡§707-710
  11. °ëë½ÓÌÀ¡¤µÈ¼¶©»Ë¡¤Æþß·Á¿ù»³Í´Éס¤×¢ÅÄÂîÌ顤ÌÚ²¼Íøɧ ; ÍÛÀ­¡¦±¢À­´¶¾ð¤ÈǾÅŰ̳èưȯÀ¸¸»¡¥Î×¾²¿À·ÐÀ¸Íý³Ø30:102¡¾108
  12. °ëë½ÓÌÀ¡¤ºûÅĶ¯Ê¼¡¤¿ùËÜãºÈ¡¤ÆîÃҵס¤±ÛÃÒͧ»Ò¡¤¿¥ÅÄ͵¹Ô¡¤¹âÀ¥¾¡¶µ¡¤ÌÚ²¼Íøɧ ; ¼ï¡¹¤ÎºÅ̲°Å¼¨¤Ë¤è¤ë¼«Î§¿À·Ðµ¡Ç½¤ÎÊѲ½-¿´ÅÅ¿ÞR-R´Ö³ÖÊÑÆ°·¸¿ô¤ò»Øɸ¤È¤·¤Æ-¡¥ºÅ̲¤È²Ê³Ø17¡§23-27
  13. Æþß· Á µÈ¼¶©»Ë¡¤ °ëë½ÓÌÀ¡¤ºØƣľ̦¡¤ÌøÀ¸Î´»ë¡¤ÌÚ²¼Íøɧ ; ̤ÉþÌôÀº¿ÀʬÎöɼԤÎǾÅŰ̾칽¤¤Ë¤Ä¤¤¤Æ¡¤ÆüËÜÌôʪǾÇȳزñ»¨»ï4 :81-83
  14. ±ÛÃÒͧ»Ò¡¤¿¥ÅÄ͵¹Ô¡¤ÌøÀ¸Î´»ë¡¤±ä¸¶·òÆó¡¤ÌÚ²¼Íøɧ ; ¸íÄ´ºÞ¤Çȯ¾É¤·¤¿µÞÀ­ phenytoinÃæÆǤÎÎ×¾²·Ð²á¡¥Âçºå¤Æ¤ó¤«¤ó¸¦µæ²ñ»¨»ï13:1-7
  15. Æþß·ÁÌøÀ¸Î´»ë¡¤ÌÚ²¼Íøɧ ; ƶ»¡¤Ë˳¤·¤¤¶¯Ç÷¾É¾õ¤ËÂФ·¤Æfluvoxamine+risperidone¼£ÎŤ¬ÁÕ¸ú¤·¤¿1Îã¡¥¶¯Ç÷À­¾ã³²¤Î¸¦µæ3:75-80
  16. µÈÅľ﹧¡¤²ÏÁêµÈ¡¤µÈ¼¶©»Ë¡¤Æî Ãҵס¤ÌÚ²¼Íøɧ¡¤ ß·ÅÄÉÒ ; 99mTc-ECD SPECT¤òÍѤ¤¤¿¤¦¤ÄɤÎǾ·ìήɾ²Á¡¥ÆüËܲèÁü°å³Ø»¨»ï21(2 ):61-66
  17. óîÆ£¹¬»Ò¡¤°ÂÊÝÈ¥»Ò¡¤Í­Ìڱʻҡ¤µÈÅľ﹧¡¤ÅĶᰡÍö¡¤ÌøÀ¸Î´»ë¡¤ÌÚ²¼Íøɧ ; Ãæǯ´üȯ¾É³Îǧ¶¯Ç÷ÃËÀ­¤Î¼£Îŷвá¤Ë¤Ä¤¤¤Æ¡¥¶¯Ç÷À­¾ã³²¤Î¸¦µæ3:109-113
  18. ÌÚ²¼Íøɧ¡¤º½¸¶ÀéÊ桤ʡÅçÀµ¿Í¡¤ÅĶᰡÍö ; Âç³Øɱ¡¤Ë¤ª¤±¤ëÀº¿À²Ê¥ê¥Ï¥Ó¥ê¥Æ¡¼¥·¥ç¥ó¤ÎÌò³ä¡¥Àº¿À¿À·Ð³Ø»¨»ï104(3)201-209

¥Ú¡¼¥¸TOP¤ØÌá¤ë

ÁíÀ⡦²òÀâ

  1. °ëë½ÓÌÀ¡¤ÌÚ²¼Íøɧ ; ¿À·Ð¾É¸õ·²¡½¤Æ¤ó¤«¤ó¾É¸õ·²¡½­º¡¥ÆüËÜÎ×à®379-384
  2. ¹âÀ¥¾¡¶µ¡¤ÌÚ²¼Íøɧ ; ¥Ñ¥Ë¥Ã¥¯¾ã³²¼£ÎŤΥ¹¥È¥é¥Æ¥¸¡¼¡¥½èÊýÌôºÞ¤ÎÉûºîÍÑȯ¸½»þ¤ÎÂкö ; 94-99
  3. ¾¾ËÜ°ìÀ¸¡¤ÌÚ²¼Íøɧ ; Ķ¹âÎð¼Ô¤ÎÀº¿À¼À´µ¤ÎÆÃħ¡¥Ï·Ç¯Àº¿À°å³Ø»¨»ï13(8)¡§921-925

¥Ú¡¼¥¸TOP¤ØÌá¤ë